Open AccessAn Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis
Author(s) -
Jindra Windrichová,
Radek Kučera,
Radka Fuchsová,
Ondřej Topolčan,
Ondřej Fiala,
Jana Svobodová,
Jindřich Fínek,
D Slípková
Publication year - 2018
Publication title -
technology in cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 63
eISSN - 1533-0346
pISSN - 1533-0338
DOI - 10.1177/1533033818807466
Subject(s) - medicine , bone metastasis , osteonectin , oncology , cancer , risk factor , prostate cancer , metastasis , bone scintigraphy , bone disease , pathology , osteoporosis , radiology , biology , alkaline phosphatase , osteocalcin , biochemistry , enzyme
We identified growth differentiation factor-15 as the best individual marker for bone metastasis diagnostics. The best formula for risk score includes levels of 3 biomarkers-procollagen type 1 N-terminal propeptide, growth differentiation factor-15, and osteonectin. The new score has better performance described by higher area under the curve than individual biomarkers. A further study is necessary to confirm these findings incorporating a larger number of patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom